Excess sodium intake may increase the risk of eczema flares

FHS
June 5, 2024
6:45 pm

UCSF study finds that changes in daily salt intake may explain eczema flares.

(Favezelimab + pembrolizumab) by Merck for Bladder Cancer: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

November 5, 2023

New score predicts risk of postoperative liver failure with high accuracy

Surgical removal of parts of the liver remains the only curative approach for patients with liver-specific cancer.

November 2, 2023

Incyte acquires global rights to MorphoSys’ tafasitamab

Share this article A CD19-targeting immunotherapy, tafasitamab is approved as a combination regimen to treat B-cell lymphoma. Credit: CI Photos / Shutterstock.com. Incyte has acquired

February 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.